clinical trials

News

Steve Davis, president and chief executive of Acadia Pharma

Acadia pulls trials of pimavanserin after schizophrenia fail

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.

News

AAD: Sanofi showcases data on possible Dupixent successor

Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2

R&D

This week in clinical trials: 12th to 16th February 2024

In this instalment of our week-by-week clinical trials round-up, we look at life sciences research and development announced during the week of 12th to 16th February, from early-stage onwar

News

AAD: J&J’s oral IL-23 drug shows durability in psoriasis

Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to a durable ef

R&D

Enhancing clinical trials: The case for algorithmic prespeci...

In the dynamic world of clinical trials, innovative methods are vital to improving the efficiency and reliability of medical research.

News

Justin Klee and Joshua Cohen, co-CEOs of Amylyx Pharma

Amylyx plummets as confirmatory trial of ALS drug fails

Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putti

Acadia pulls trials of pimavanserin after schizophrenia fail

AAD: Sanofi showcases data on possible Dupixent successor

This week in clinical trials: 12th to 16th February 2024

AAD: J&J’s oral IL-23 drug shows durability in psoriasis

Enhancing clinical trials: The case for algorithmic prespeci...

Amylyx plummets as confirmatory trial of ALS drug fails

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

clinical trials

Editor's Picks